XML 39 R27.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangible Assets - Additional Information (Detail) - USD ($)
3 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Finite Lived Intangible Assets [Line Items]    
Amortization expense $ 438,991 $ 13,664
Amortization of license agreements remainder of fiscal year 2016 1,275,322  
Amortization of license agreements in 2017 1,700,429  
Amortization of license agreements in 2018 1,700,429  
Amortization of license agreements in 2019 1,700,429  
Amortization of license agreements in 2020 1,700,429  
Amortization of license agreements in 2021 1,700,429  
Amortization of license agreements, thereafter $ 13,662,723  
Novartis | Licensing Agreements    
Finite Lived Intangible Assets [Line Items]    
Amortization period of intangible assets 21 years  
Finite-lived intangible assets, accumulated amortization $ 123,671  
Novartis | Patents    
Finite Lived Intangible Assets [Line Items]    
Amortization period of intangible assets 14 years  
Finite-lived intangible assets, accumulated amortization $ 1,293,353  
Roche RNAi | Licensing Agreements    
Finite Lived Intangible Assets [Line Items]    
Amortization period of intangible assets 4 years  
Finite-lived intangible assets, accumulated amortization $ 230,000